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Background: Breast cancer is a heterogeneous disease consisting of different subtypes. Trichorhinophalangeal syndrome
type 1 (TRPS1) gene, a GATA-type transcription factor, has been found to be highly expressed in breast cancer.
Epithelial-to-mesenchymal transition (EMT) is known to play an important role in tumour invasion and metastasis.
Our objective was to elucidate the different roles and clinical relevance of TRPS1 in different estrogen receptor
(ER) expression subtypes of breast cancer.
Methods: An immunohistochemical study was performed. The correlation between clinicopathological features
and other biomarker profiles were analysed statistically.
Result: TRPS1 expression was correlated with the patients’ age (P = 0.017). It was positively related with ERα (P < 0.001),
progesterone receptor (PR) (P < 0.001) and ERβ (P = 0.001) status, but negatively associated with Ki67 (P = 0.002) and
HER2 (P = 0.025) status. In ERα-positive breast cancer, TRPS1 expression was positively associated with the expression of
E-cadherin (P < 0.001), β-catenin(P = 0.001), ERβ (P = 0.03), and p53 (P = 0.002) status, while in ERα-negative breast
cancer, TRPS1 expression was correlated with slug (P = 0.004), vimentin (P = 0.003), smooth muscle actin (SMA)
(P = 0.031), and IMP3 (P = 0.005) expression.
Conclusions: Based on our findings, we conclude that TRPS1 is positively associated with E-cadherin and β-catenin
status in ERα-positive breast cancer cells, while it is also significantly associated with mesenchymal markers of EMT in
ERα-negative breast cancer cells. TRPS1 can be a prognostic marker depending on the type of breast cancer.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
8686515681264281
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Breast cancer is one of the most common cancers in
women, accounting for more than 1,300,000 cases and
450,000 deaths worldwide each year [1]. Breast cancer is a
heterogeneous disease that comes in different morpho-
logical and immunohistochemical characteristics with cor-
responding clinical behaviour [2]. The oncogenesis and
progression of breast cancer is a complex process involv-
ing a variety of transcription factors, activation of onco-
genes, and inactivation of tumour suppressor genes [3,4].* Correspondence: zhougy@sdu.edu.cn
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unless otherwise stated.Recently gene expression profiling and immunohisto-
chemistry (IHC) studies have been identified Tricho-rhino-
phalangeal syndrome-1 gene (TRPS1), a new GATA family
member, to be highly prevalent gene in breast cancer [5,6].
TRPS is an autosomal dominant genetic disorder char-
acterised by craniofacial and skeletal anomalies due to
mutations or deletions of the TRPS1 gene. It is composed
of nine zinc finger motifs including a single GATA-type
DNA-binding domain flanked by two potential nuclear lo-
calisation signals (NLS) and two C-terminal zinc fingers
closely related to the domain found in the Ikaros family of
lymphoid transcription factors [7]. It has been demon-
strated that TRPS1 is a transcriptional repressor and its
activities are dependent on both the highly conservedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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finger motifs [8]. For example, TRPS1 can repress Stat3
to regulate proliferation and apoptosis of chondrocytes.
TRPS1 controls epithelial proliferation through repres-
sing SOX9 in the developing vibrissa follicle in mice. It
can also repress the expression of Runx2, a key regula-
tor of osteoblastogenesis and chondrocyte maturation
[9]. Moreover, TRPS1 can suppress the osteocalcin ex-
pression through binding to its promoter [10].
As mentioned before, TRPS1 gene in human has been
found to be overexpressed in breast cancer, expressed in
more than 90% estrogen receptor α (ERα) positive and
negative breast cancer subtype [6]. The gene is localised
on human chromosome 8q23–24.1, a region highly amp-
lified in several cancers, especially in prostate and breast
cancer. It is important to note that TRPS1 gene has been
found to be highly expressed not only in the mammary
glands but also in prostate, testis, ovaries, kidneys, and
lungs [11]. Increasingly, there are more evidences to sug-
gest the involvement of TRPS1 in a variety of functions
in human cancers [12-15].
Recent studies have reported that TRPS1 can regulate
mesenchymal-to-epithelial transition (MET) during em-
bryonic development in a number of tissues, including
kidneys, cartilages, and bones [10,16,17]. Epithelial-to-
mesenchymal transition (EMT) was first recognised as
an important process during normal embryonic develop-
ment [18]; however, carcinoma cells are also capable of
reactivating EMT during tumour progression [19,20].
During this transition, tumour cells lose epithelial char-
acteristics such as cell apical-basal polarity, membrane-
associated adherents, and cell-to-cell adhesion protein
E-cadherin. Concurrently, these tumour cells also undergo
a dramatic remodelling of the cytoskeleton to facilitate cell
mortality and invasion; the cells are also transformed to
obtain a spindle-like phenotype. A key feature of EMT is a
gene switch, resulting in downregulation of E-cadherin
and upregulation of vimentin, smooth muscle actin. Tran-
scriptional factors, such as snail, slug, and twist, which
function by suppressing the expression of epithelial spe-
cific adhesion molecules, such as E-cadherin, were un-
veiled as key regulators inducing EMT in breast cancer
and other cancers [21-24]. β-catenin was first identified as
a protein that binds with E-cadherin to maintain cell-to-
cell adhesion; however, it also functions as a transcription
factor. Loss of membranous β-catenin expression and
gain of cytoplasmic or nuclear β-catenin expression in
neoplastic glands have been related to carcinogenesis and
tumour progression in gastrointestinal cancers [25,26].
Thus, by detecting these EMT markers, one can roughly
estimate the tumour cells undergoing EMT from non-
EMT tumour cells.
In addition to the involvement of TRPS1 in regulating
MET, it has also been found to repress ZEB2, a keyregulator of EMT that inhibits E-cadherin and other epi-
thelial genes [12]. Realizing the potential of TRPS1 gene
as the new EMT marker, we focused our work in eluci-
dating different roles and clinical relevance of TRPS1 in
ERα-positive and ERα-negative breast cancer subtypes.
Methods
Patients and tissue samples
This study was conducted on 180 paraffin-embedded
breast samples, which were histopathologically diagnosed
invasive ductal carcinoma during 2007 to 2009 at the
Department of Pathology of Qilu Hospital of Shandong
University. For using these clinical materials for research
purposes, prior patient consent and approvals from the
Research Ethics Committee of Shandong Medical Univer-
sity were obtained. All the diagnoses were made following
the Pathology and Genetics of Tumours of the Breast and
Female Genital Organs of World Health Organisation
Classification of Tumours.
Tissue microarray
For each hematoxylin and eosin (H&E)-stained slide, two
representative areas were selected and the corresponding
spots were marked on the surface of the paraffin block.
Using a tissue microarray (TMA) punching instrument,
the selected areas were punched out and were placed into
the recipient block side by side. Each tissue core was
2 mm in diameter and was assigned with a unique TMA
location number that was linked to a database containing
other clinicopathologic data [27].
Immunohistochemistry
The immunohistochemical study was carried out to exam-
ine altered protein expression in 180 paraffin-embedded
breast tissues as described in previous publications [28].
All the markers were incubated with the sections
overnight at 4°C; the markers included TRPS1 (sc-26974,
diluted 1:200; Santa Cruz Biotechnology, CA, USA), P53
(Zhongshan Golden Bridge Biotechnology, ZSGB-Bio,
Beijing, China), E-Cadherin (24E10, diluted 1:400, Cell
Signalling Technology, USA), mouse monoclonal antibody
β-catenin (E-5, diluted 1:500, Santa Cruz Biotechnology,
CA, USA), Vimentin ( D21H3, diluted 1:100, Cell Sig-
nalling Technology, USA), slug (C19G7, diluted 1:50,
Cell Signalling Technology, USA); the second antibody
was from IHC reagent kit (Zhongshan Biotechnology
Company, Beijing, China). After diaminobenzidine (DAB)
staining, the sections were counterstained with hematoxylin.
For negative controls, the antibodies were replaced with
phosphate buffered saline (PBS).
Evaluation of immunohistochemical staining
The stained slides were reviewed and evaluated independ-
ently by two observers blinded to patients’ information. A
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tensity as well as percentage of positive cells, was used
to evaluate the protein staining. In brief, staining of
TRPS1 was scored semi-quantitatively for intensity (0 = no
expression, 1 = weak, 2 =moderate, and 3 = strong) and
percentage of positive cells (0 = 0–10%, 1 = 10–30%, 2 =
30–50%; 3 = 50–80%, and 4 = 80–100%). The final score
of TRPS1 was the staining score multiplied by the per-
centage of positive cells. The following cut-off levels
were applied: 0 for negative and ≥ 1 for positive [15].
For β-catenin, membrane and cytoplasmic/nuclear ex-
pression were recorded separately as no staining, weak
staining, or strong staining. Cases with more than 50%
of nuclei stain were considered nuclear staining while
cases with more than 50% of cytoplasm stain were consid-
ered cytoplasmic staining [29]. ER or PgR was positive if 1%
of tumour cell nuclei were immuno reactive [30]. For other
molecular markers, tumours were regarded as immune-
positive if > 10% of tumour cells showed immunoreactivity.
Cytoplasmic staining was considered positive for vimentin
and SMA. Nuclear staining was considered positive for
TRPS1, ERβ, slug and P53. Membranous staining was con-
sidered positive for E-cadherin.
Statistical analysis
Statistical analyses were performed using the statistics soft-
ware package SPSS 18.0 (SPSS, Chicago, IL). Chi-square
test or Fisher’s exact test were performed to evaluate the
correlation between TRPS1 expression and clinicopatho-
logic characteristics, if appropriate. Bivariate correlations
between study variables were calculated by Spearman’s
rank correlation coefficients. Differences were consid-
ered statistically significant for P values < 0.05.
Results
Relationship of TRPS1 over-expression with the clinical
features in breast cancer
In the analysis of a 180-member TMA, we found posi-
tive TRPS1 expression in 93 cases (51.7%), while 87 tu-
mours (48.3%) were negative. Table 1 shows no significant
correlation between the expression level of TRPS1 and
biological factors such as histology grade (P = 0.903),
pathological stage (P = 0.646), tumour size (P = 0.343),
lymph node metastasis (P = 0.443), P53 status (P = 0.113),
and IMP3 status (P = 0.618). In contrast, we found that
TRPS1 expression was strongly correlated with the pa-
tients’ age (P = 0.017), Ki67 (P = 0.002), ERα (P < 0.001),
progesterone receptor (PR) (P < 0.001), HER2 (P = 0.025),
and ERβ status (P = 0.001). Spearman correlation ana-
lysis was preformed to confirm further the correlation
between TRPS1 expression and patients’ age (−0.179,
P = 0.016); Ki67 (−0.233, P = 0.002), ERα (0.333, P < 0.001),
PR (0.31, P < 0.001), HER2 (−0.166, P = 0.025), and ERβ
status (0.242, P = 0.001). We divided the patients into twogroups as ERα-positive and ERα-negative. TRPS1 expres-
sion was observed in 69 (65.7%) of 105 ERα-positive pa-
tients, while in 24 (32%) of 75 ERα-negative patients.
Relationship of TRPS1 expression with EMT markers in
breast cancer
As TRPS1may be a critical regulator of EMT during breast
cancer initiation and progression, the expression of EMT
markers, including E-cadherin, β-catenin, vimentin, SMA
and slug, were stained in human breast cancer TMA. Stat-
istical analysis indicated that the immunohistochemical ex-
pression of TRPS1 is directly correlated with E-cadherin
(P = 0.002) and β-catenin (P = 0.003), which was further
confirmed by Spearman correlation analysis (E-cadherin:
r = 0.231, P = 0.002; β-catenin: r = 0.221, P = 0.003) (Table 1).
Moreover, we also found that TRPS1 expression was signifi-
cantly correlated with slug (P = 0.019), vimentin (P = 0.022)
and SMA (P = 0.039); the corresponding Spearman correl-
ation values are 0.186 (P = 0.012), 0.171 (P = 0.022), and
0.154 (P = 0.039).
Correlation between TRPS1 expression and molecular
markers in ERα-positive breast cancer
We analysed the molecular markers in ERα-positive breast
cancer. Table 2 shows the expression of TRPS1 is posi-
tively associated with E-cadherin (P < 0.001), β-catenin
(P = 0.001), ERβ (P = 0.03), and p53 (P = 0.002) status
(Figure 1). However, the TRPS1 expression is not asso-
ciated with slug (P = 0.549), vimentin (P = 0.296), SMA
(P = 0.296), and IMP3 (P = 0.605).
Correlation between TRPS1 expression and molecular
markers in ERα-negative breast cancer
For ERα negative breast cancer cases, Table 3 shows that
the immunohistochemical expression of TRPS1 has cor-
relation with slug (P = 0.004), vimentin (P = 0.003), SMA
(P = 0.031), and IMP3 (P = 0.005), which was further con-
firmed by Spearman correlation analysis (Figure 2).
Discussion
Breast cancer is a heterogeneous disease consisting of
multiple molecular subtypes. The presence of hormone
receptors ER, PR, and human EGFR-2 (HER-2) are sig-
nificantly meaningful in therapeutic decision-making for
patients with breast cancer. In addition, these factors
may also predict the probability of disease relapse. Hor-
mone receptor-positive tumours have favourable outcomes
because of their response to endocrine manipulations such
as tamoxifen, aromatase inhibitors, or ovarian ablation
[31]. Tumours with ERα-negative phenotype tend to have
poor prognosis, unlike their hormone receptor or HER-2
positive counterparts; hence, such ERα-negative tumours
lack targeted therapeutics.
Table 1 Correlation between TRPS1 expression and the clinicopathologic characteristics of breast cancer patients
Characteristics n TRPS1 expression P value Spearman Value (r) P value
Negative Positive Correlation
Age(y)
≤50 70 26 44 0.017 −0.179 0.016
>50 110 61 49
Grade
I 11 5 6 0.903
II 124 59 65
III 45 23 22
Pathological stage
I 49 23 26 0.646
II 85 44 41
III 46 20 26
Tumor size
<2 60 26 34 0.343
≥2 120 61 59
Lymph node metastasis
Negative 94 48 46 0.443
Positive 86 39 47
Expression of Ki67
≤25% 62 20 42 0.002 −0.233 0.002
>25% 118 67 51
Expression of P53
Negative 72 40 32 0.113
Positive 108 47 61
ERα
Negative 75 51 24 <0.001 0.333 <0.001
Positive 105 36 69
PR
Negative 75 50 25 <0.001 0.31 <0.001
Positive 105 37 68
HER-2
Negative 124 53 71 0.025 −0.166 0.025
Positive 56 34 22
E-cadherin
Negative 33 24 9 0.002 0.231 0.002
Positive 147 63 84
Slug
Negative 170 86 84 0.019 0.186 0.012
Positive 10 1 9
Vimentin
Negative 165 84 81 0.022 0.171 0.022
Positive 15 3 12
SMA
Negative 169 85 84 0.039 0.154 0.039
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Table 1 Correlation between TRPS1 expression and the clinicopathologic characteristics of breast cancer patients
(Continued)
Positive 11 2 9
β-catenin
Negative 67 42 25 0.003 0.221 0.003
Positive 113 45 68
ERβ
≤2 92 55 37 0.001 0.242 0.001
>2 87 31 56
IMP3
Negative 157 77 80 0.618
Positive 23 10 13
Table 2 Correlation between TRPS1 expression and molecular markers in ERα positive breast cancer patients
Characteristics n TRPS1 expression P value Spearman Value (r) P value
Negative Positive Correlation
Age(y)
≤50 42 9 33 0.023 −0.221 0.023
>50 63 27 36
Expression of P53
Negative 45 23 22 0.002 0.307 0.001
Positive 60 13 47
E-cadherin
Negative 16 13 3 <0.001 0.42 <0.001
Positive 89 23 66
Slug
Negative 102 36 66 0.549
Positive 3 0 3
Vimentin
Negative 101 36 65 0.296
Positive 4 0 4
SMA
Negative 101 36 65 0.296
Positive 4 0 4
β-catenin
Negative 34 19 15 0.001 0.315 0.001
Positive 71 17 54
ERβ
≤2 46 21 25 0.03 0.211 0.03
>2 59 15 44
IMP3
Negative 101 34 67 0.605
Positive 4 2 2
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Figure 1 Expression of markers in ERα-positive breast cancer (Magnification 200X). A. Positive nuclear staining for TRPS1, B. Positive membranous
staining for E-cadherin, C. Positive membranous staining for β-catenin, D. Positive nuclear staining for ERβ, and E. Positive nuclear staining for P53.
Table 3 Correlation between TRPS1 expression and molecular markers in ERα negative breast cancer patients
Characteristics n TRPS1 expression P value Spearman Value (r) P value
Negative Positive Correlation
Age(y)
≤50 28 17 11 0.296
>50 47 34 13
Expression of P53
Negative 27 17 10 0.483
Positive 48 34 14
E-cadherin
Negative 17 11 6 0.741
Positive 58 40 18
Slug
Negative 68 50 18 0.004 0.369 0.001
Positive 7 1 6
Vimentin
Negative 64 48 16 0.003 0.362 0.001
Positive 11 3 8
SMA
Negative 68 49 19 0.031 0.271 0.019
Positive 7 2 5
β-catenin
Negative 33 23 10 0.78
Positive 42 28 14
ERβ
≤2 46 34 12 0.167
>2 29 17 12
IMP3
Negative 56 43 13 0.005 0.323 0.005
Positive 19 8 11
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Figure 2 Expression of markers in ERα-negative breast cancer (Magnification 200X). A. Positive nuclear staining for TRPS1, B. Positive
cytoplasmic staining for vimentin, C. Positive nuclear staining for slug. D. Positive cytoplasmic staining for SMA, and E. Positive cytoplasmic
staining for IMP3.
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mary human breast cancer samples and explored its asso-
ciation with major breast tumour histological specialties
and patients’ clinical characteristics. TRPS1 was positively
associated with ER and PR expressions and negatively as-
sociated with HER2 status, which is consistent with previ-
ous study [6].
When the cut-off level score for TRPS1 to be positive
is 1, the TRPS1 was not remarkably associated with the
tumour grade, pathological stage, tumour size and lymph
node metastasis. However, upon changing the cut-off
level score of TRPS1 to be positive as ≥ 2, TRPS1 was
found to be positively associated with lymph node me-
tastasis and P53 status (data not shown).
However, previous studies showed that higher TRPS1
expression, when analysed using univariate and multi-
variate models, predicted better overall survival (OS)
and disease-free survival (DFS) in a subgroup of ERα+,
stage I/II breast cancer patients who received endocrine
therapy only [32]. Recent studies have also confirmed
that high TRPS1 expression was significantly associated
with lymph node metastasis and higher pathological
stage of patients with colon cancer [14]. All these find-
ings support our hypothesis that TRPS1 may not merely
be an indicator of better prognosis as shown in other
studies. However, further research using larger patient
cohort and more breast cancer cell lines is required to
elucidate this contradictory result.
Epithelial cancer cells attain mesenchymal features that
make them easier to invade the surrounding tissues and
metastasise during EMT process. We used IHC to analyse
these markers in 180 patients. Although TRPS1 was sig-
nificantly associated with E-cadherin and β-catenin, it was
also positively associated with mesenchymal markers suchas vimentin, SMA, and slug. The above data did not com-
ply with previous results that TRPS1 inhibits EMT process
in breast cancer progression [12]. Hence, we divided the
patients into two groups as ERα-positive and ERα-
negative and reanalysed these EMT markers. Surprisingly,
in ERα-positive breast cancer, we found TRPS1 to be posi-
tively associated with E-cadherin and β-catenin status with
no significant correlation with any of the mesenchymal
markers. Consistent with our hypothesis, significant asso-
ciation was also found between TRPS1 expression and E-
cadherin expression in ERα + breast cancer cases [32]. In
ERα-negative breast cancer, we found TRPS1 to be posi-
tively associated with vimentin, SMA and slug. TRPS1 was
also found to be positively related with IMP3, which is
expressed preferentially in triple negative breast cancers
(TNBC). IMP3 is a member of insulin-like growth factor
II (IGF-II) mRNA-binding proteins family. It contributes
to the migration and invasion of TNBC cells. Thus,TRPS1
may be associated with the migration, invasion, and EMT
in ERα-negative breast cancer cells. Ligand-activated ERα
could suppress slug transcription through direct associ-
ation with the slug promoter. Human breast cancers,
which lack ligand-activated ERα, may then over-express
slug that may downregulate E-cadherin and lead to EMT
[33]. We found TRPS1 to be associated with different
EMT markers by different ERα status, therefore, ERα
might play an important role in affecting the relationship
between TRPS1 and EMT markers.
Estrogen receptors include estrogen receptor α (ERα)
and estrogen receptor β (ERβ). Most studies have provided
evidence that ERβ acts as a negative modulator of ERα and
indicates a good prognosis with prolonged DFS [34,35].
Several investigators have found ERβ expression to be posi-
tively correlated with poor prognostic phenotypes such as
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negative breast cancer [36,37]. We also stained ERβ and
found its expression to be correlated with TRPS1 expres-
sion. TRPS1 expression was not regulated by ER signalling
since estrogen withdrawal using charcoal-stripped serum
did not affect TRPS1 gene or protein expression in ERα-
positive breast cancer cell lines [32]. Thus, we have as-
sumed that TRPS1 might transcriptionally both regulate
genes and affect tumour growth and development to vary-
ing degrees.
Conclusions
There are many possible explanations for the different
association between the molecular markers with TRPS1
in ERα-positive and ERα-negative breast cancer. First,
TRPS1 is capable of binding to numerous cofactors of
various functions. Second, it may either promote or in-
hibit carcinoma processing depending on the context
and amount of protein present [38,39]. Based on the
above results, we conclude that TRPS1 is positively associ-
ated with E-cadherin and β-catenin status in ERα-positive
breast cancer, while it also has a significant association
with mesenchymal markers of EMT in ERα-negative
breast cancer. However, further studies with large number
of tumours and breast cancer cell lines are required to val-
idate the precise function of TRPS1 gene in breast cancer.
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